BioRestorative Therapies is a clinical-stage biotech developing cell-based therapies using adult stem cells, with a small commercial biocosmeceuticals business. The company has 14 employees and operates a cGMP-certified lab in Melville, New York. BioRestorative's lead program is BRTX-100, an autologous stem cell therapy for chronic lower back pain caused by degenerative disc disease. BRTX-100 is made from a patient's own bone marrow-derived mesenchymal stem cells, cultured under hypoxic conditions to improve cell survival, then injected directly into the damaged disc in an outpatient procedure. The FDA granted Fast Track designation to BRTX-100 in early 2025, and BioRestorative is targeting a Phase 3 IND submission in 2026 following an accelerated BLA pathway discussion with the FDA. If approved, BioRestorative intends to commercialize BRTX-100 as a per-treatment product marketed to pain management physicians and spinal surgeons, or alternatively license it to a strategic partner. BioRestorative also has a pre-clinical program called ThermoStem, which develops brown adipose tissue-derived stem cell therapies for obesity and metabolic disorders, and is pursuing a licensing deal for this program rather than self-funding clinical trials. The company's only current revenue comes from selling a cell-based cosmetic serum to medical spas, distributors, and consumers. BioRestorative funds operations through equity issuances and will require substantial additional capital to advance its pipeline.